BHC vs. VRX, APHA, TLRY, CRON, THCX, WEED, GUD, ACB, FIRE, and CRDL
Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include Valeant Pharmaceuticals International (VRX), Aphria (APHA), Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), Canopy Growth (WEED), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), and Cardiol Therapeutics (CRDL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Valeant Pharmaceuticals International (TSE:VRX) and Bausch Health Companies (TSE:BHC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
Bausch Health Companies has a consensus price target of C$9.00, suggesting a potential upside of 0.56%.
In the previous week, Bausch Health Companies had 6 more articles in the media than Valeant Pharmaceuticals International. MarketBeat recorded 7 mentions for Bausch Health Companies and 1 mentions for Valeant Pharmaceuticals International. Bausch Health Companies' average media sentiment score of 0.67 beat Valeant Pharmaceuticals International's score of -0.08 indicating that Valeant Pharmaceuticals International is being referred to more favorably in the media.
Valeant Pharmaceuticals International received 427 more outperform votes than Bausch Health Companies when rated by MarketBeat users. However, 66.10% of users gave Bausch Health Companies an outperform vote while only 65.27% of users gave Valeant Pharmaceuticals International an outperform vote.
Valeant Pharmaceuticals International has a net margin of 0.00% compared to Valeant Pharmaceuticals International's net margin of -5.07%. Bausch Health Companies' return on equity of 0.00% beat Valeant Pharmaceuticals International's return on equity.
Valeant Pharmaceuticals International has higher earnings, but lower revenue than Bausch Health Companies.
80.0% of Bausch Health Companies shares are held by institutional investors. 0.9% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Bausch Health Companies beats Valeant Pharmaceuticals International on 6 of the 10 factors compared between the two stocks.
Get Bausch Health Companies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch Health Companies Competitors List
Related Companies and Tools
